Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.
Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Deroche L, et al. Among authors: prouvensier l. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. Antimicrob Agents Chemother. 2023. PMID: 37695298 Free PMC article.
Caspase-1-driven neutrophil pyroptosis and its role in host susceptibility to Pseudomonas aeruginosa.
Santoni K, Pericat D, Gorse L, Buyck J, Pinilla M, Prouvensier L, Bagayoko S, Hessel A, Leon-Icaza SA, Bellard E, Mazères S, Doz-Deblauwe E, Winter N, Paget C, Girard JP, Pham CTN, Cougoule C, Poincloux R, Lamkanfi M, Lefrançais E, Meunier E, Planès R. Santoni K, et al. Among authors: prouvensier l. PLoS Pathog. 2022 Jul 18;18(7):e1010305. doi: 10.1371/journal.ppat.1010305. eCollection 2022 Jul. PLoS Pathog. 2022. PMID: 35849616 Free PMC article.
An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates.
Aubry R, Buyck J, Prouvensier L, Decousser J-W, Nordmann P, Wicha SG, Marchand S, Grégoire N. Aubry R, et al. Among authors: prouvensier l. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0030123. doi: 10.1128/aac.00301-23. Epub 2023 Sep 8. Antimicrob Agents Chemother. 2023. PMID: 37681977 Free PMC article.
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher K, Morrissey I, Soulama-Mouze C. Escaich S, et al. Among authors: prouvensier l. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. doi: 10.1128/AAC.01248-10. Epub 2011 Aug 8. Antimicrob Agents Chemother. 2011. PMID: 21825292 Free PMC article.
EEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruption.
Pinilla M, Mazars R, Vergé R, Gorse L, Paradis M, Suire B, Santoni K, Robinson KS, Toh GA, Prouvensier L, Leon-Icaza SA, Hessel A, Péricat D, Murris M, Guet-Revillet H, Henras A, Buyck J, Ravet E, Zhong FL, Cougoule C, Planès R, Meunier E. Pinilla M, et al. Among authors: prouvensier l. J Exp Med. 2023 Oct 2;220(10):e20230104. doi: 10.1084/jem.20230104. Epub 2023 Aug 29. J Exp Med. 2023. PMID: 37642996 Free PMC article.
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec G, Oliveira C, Desroy N, Raymond C, Peltier L, Moreau F, Escaich S, Vongsouthi V, Floquet S, Drocourt E, Walton A, Prouvensier L, Saccomani M, Durant L, Genevard JM, Sam-Sambo V, Soulama-Mouze C. Gerusz V, et al. Among authors: prouvensier l. J Med Chem. 2012 Nov 26;55(22):9914-28. doi: 10.1021/jm301113w. Epub 2012 Oct 23. J Med Chem. 2012. PMID: 23092194
11 results